Daniel Steiner

Daniel Steiner

Auto-generated profile, based on publicly available information

Daniel Steiner

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2024 in Blood
Verified
Journal Article
Closed access
CECornelia Englisch
Cornelia Englisch
FMFlorian Moik
Florian Moik
DSDaniel Steiner
Daniel Steiner
ASAngelika M. Starzer
Angelika M. Starzer
ABAnna S. Berghoff
Anna S. Berghoff
Cihan AyCihan Ay
Cihan Ay
Hemostatic imbalances are frequent in patients with cancer. Although cancer-associated thrombotic complications have been well characterized, data on bleeding events in patients with cancer are sparse. Therefore, we aimed to investigate the incidence, risk factors, and impact on prognosis of bleeding events in patients with cancer initiating systemic anticancer therapies in a prospective cohort study, the Vienna Cancer, Thrombosis, and Bleeding Study. The primary study outcome was defined as clinically relevant bleeding (CRB), comprising major bleeding (MB) and clinically relevant nonmajor bleeding. In total, 791 patients (48% female), with median age of 63 years (interquartile range [IQR], 54-70), with various cancer types, 65.5% stage IV, were included. Over a median follow-up of 19 months (IQR, 8.7-24.0), we observed 194 CRB events in 139 (17.6%) patients, of which 42 (30.0%) were tumor related, 64 (46.0%) gastrointestinal, and 7 (5.0%) intracerebral. The 12-month cumulative incidence of first CRB and MB was 16.6% (95% confidence interval [CI], 13.7-19.6) and 9.1% (95% CI, 6.8-11.3), respectively, in the whole cohort, and 14.4% (95% CI, 11.2-17.5) and 7.0% (95% CI, 4.7-9.2), respectively, in those without anticoagulation. Patients with head and neck cancer had the highest risk of CRB. Lower baseline hemoglobin and albumin were associated with bleeding in patients without anticoagulation. Seven (5.0%) bleeding events were fatal, of which 6 occurred in patients without anticoagulation. Patients with CRB were at an increased risk of all-cause mortality (multivariable transition hazard ratio, 5.80; 95% CI, 4.53-7.43). In patients with cancer, bleeding events represent a frequent complication and are associated with increased mortality.

20 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CSChristoph Suppan
Christoph Suppan
FPFlorian Posch
Florian Posch
HMHannah Deborah Mueller
Hannah Deborah Mueller
NMNina Mischitz
Nina Mischitz
DSDaniel Steiner
Daniel Steiner
Marija BalicMarija Balic
Marija Balic
Background: The prognostic performance of the residual cancer burden (RCB) score is a promising tool for breast cancer patients undergoing neoadjuvant therapy. We independently evaluated the prognostic value of RCB scores in an extended validation cohort. Additionally, we analyzed the association between chemotherapy dose reduction and RCB scores. Methods: In this extended validation study, 367 breast cancer patients with available RCB scores were followed up for recurrence-free survival (RFS), distant disease-free survival (DDFS), and overall survival (OS). We also computed standardized cumulative doses of anthracyclines and taxanes (A/Ts) to investigate a potential interaction between neoadjuvant chemotherapy dose reduction and RCB scores. Results: Higher RCB scores were consistently associated with adverse clinical outcomes across different molecular subtypes (HR for RFS = 1.60, 95% CI 1.33–1.93, p < 0.0001; HR for DDFS = 1.70, 95% CI 1.39–2.05, p < 0.0001; HR for OS = 1.67, 95% CI 1.34–2.08, p < 0.0001). The adverse impact prevailed throughout 5 years of follow-up, with a peak for relapse risk between 1–2 years after surgery. Clinical outcomes of patients with RCB class 1 did not differ substantially at 5 years compared to RCB class 0. A total of 180 patients (49.1%) underwent dose reduction of neoadjuvant A/T chemotherapy. We observed a statistically significant interaction between dose reduction and higher RCB scores (interaction p-value = 0.042). Conclusion: Our results confirm RCB score as a prognostic marker for RFS, DDFS, and OS independent of the molecular subtype. Importantly, we show that lower doses of cumulative neoadjuvant A/T were associated with higher RCB scores in patients who required a dose reduction.

11 December 2023 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
DSDaniel Steiner
Daniel Steiner
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
HJHelle Jørgensen
Helle Jørgensen
KLKristina Laugesen
Kristina Laugesen
CACihan Ay
Cihan Ay
HSHenrik Toft Sørensen
Henrik Toft Sørensen
Background Venous thromboembolism (VTE) may complicate the clinical course of cancer patients and add to their psychological burden. Objectives We aimed to investigate the association between VTE and risk of subsequent depression in patients with hematological cancer. Patients and Methods We conducted a population-based cohort study using Danish national health registries. Between 1995 and 2020, we identified 1,190 patients with hematological cancer and incident VTE diagnosed within 6 months before to 1 year after cancer diagnosis. A comparison cohort of patients with hematological cancer without VTE (n = 5,325) was matched by sex, year of birth, cancer type, and year of cancer diagnosis. Patients were followed until diagnosis of depression, emigration, death, study end (2021), or for a maximum of 3 years. Depression was defined as hospital discharge diagnosis of depression or ≥1 prescription for antidepressants. Absolute risks of depression were computed with cumulative incidence functions, treating death as competing event. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed using Cox proportional hazards regression models, adjusting for comorbidities. Results Depression was observed in 158 hematological cancer patients with and 585 without VTE. The 3-year absolute risks of depression were 13.3% (95% CI: 11.5–15.3%) in the VTE cancer cohort and 11.1% (95% CI: 10.3–12.0%) in the comparison cancer cohort, corresponding to a risk difference of 2.2% (95% CI: -1.8–6.5%). VTE was associated with an increased relative risk of depression (adjusted HR: 1.56, 95% CI: 1.28–1.90). Conclusion VTE was associated with an elevated risk of subsequent depression in patients with hematological cancer.

28 May 2024 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
DSDaniel Steiner
Daniel Steiner
SNStephan Nopp
Stephan Nopp
GHGeorg Heinze
Georg Heinze
DKDaniel Kraemmer
Daniel Kraemmer
OSOliver Schlager
Oliver Schlager
Cihan AyCihan Ay
Cihan Ay
Venous thromboembolism (VTE) is associated with various long-term complications. We aimed to investigate the association of clinical characteristics at VTE diagnosis with functional limitations 3 and 12 months afterward. We conducted a prospective cohort study of VTE patients, excluding patients with cancer, pregnancy, and postpartum period. Functional limitations were assessed with the post-VTE functional status (PVFS) scale (range, 0-4) within 21 days of diagnosis, after 3 and 12 months (prospectively), and 1 month before diagnosis (retrospectively). Twelve-month follow-up was only performed in patients on anticoagulation. We fitted 2 proportional odds logistic regression models for the 3- and 12-month follow-ups and computed odds ratios (ORs) with 95% bootstrap percentile confidence intervals (CIs). We included 307 patients (42% female, median age 55.6 years) with a median (IQR) PVFS scale grade of 2 (2-3) at study inclusion and 0 (0-0) before diagnosis. After 3 months, PVFS scale grade in 269 patients was 1 (0-2). Female sex (OR, 2.15; 95% CI, 1.26-4.14), body mass index (OR per 1 kg/m2 increase, 1.05; 95% CI, 1.00-1.10), functional limitations at baseline, and older age were associated with functional limitations. After 12 months, PVFS scale grade in 124 patients was 1 (0-2). Female sex (OR, 4.47; 95% CI, 2.11-16.00), history of cardiovascular/pulmonary disease (OR, 2.36; 95% CI, 1.01-6.89), and functional limitations at baseline were associated with functional limitations. Functional limitations in VTE patients improved 3 and 12 months after diagnosis but did not return to pre-VTE values. We identified clinical characteristics that could help identify patients at risk of persisting functional limitations after VTE.

24 October 2024 in Lung Cancer
Verified
Journal Article
Open access
LALeyla Ay
Leyla Ay
DSDaniel Steiner
Daniel Steiner
HFHannah Fabikan
Hannah Fabikan
OIOliver Illini
Oliver Illini
DKDagmar Krenbek
Dagmar Krenbek
MHMaximilian Hochmair
Maximilian Hochmair
Phase 3 trials of neoadjuvant immunotherapy-based regimens have shown promising outcomes in patients with resectable non-small cell lung cancer (NSCLC). However, real-world data on treatment regimens with combined chemoimmunotherapy, patient profiles, and clinical outcomes in those patients are limited. This dual-center registry-based study describes clinical patterns and outcomes of using neoadjuvant platinum-based chemoimmunotherapy in patients with resectable NSCLC. The main objective was to evaluate the proportion of patients receiving local therapy after chemoimmunotherapy. Further objectives include pathological outcome, disease-free survival (DFS), and overall survival (OS). Histological samples underwent next-generation sequencing (NGS). Seventy-two patients (median age 64.5 years (interquartile range (IQR), 59-69); 40.3 % women) were included. Prior to initiation of therapy, NGS was available in 90.3 %. Median follow-up time from date of diagnosis was 374 days (IQR, 241-605). After neoadjuvant therapy, 46 patients underwent surgery and 23 radiotherapy, resulting in 69 patients receiving local therapy. Out of 46 patients who underwent surgery, 22 had pathological complete remission (PR), 11 major PR, and 12 minor PR. DFS (95 % confidence interval (CI)) in 43 (out of 46) surgical patients with R0 resection was 98 % (93-100), 98 % (93-100) and 81 % (57-100) after 180, 360 and 720 days, respectively. OS (95 % CI) was 97 % (94-100), 90 % (82-99) and 90 % (82-99), after 180, 360 and 720 days, respectively. Following neoadjuvant chemoimmunotherapy, the majority of resectable early-stage NSCLC patients could undergo local therapy in routine clinical practice. This was associated with favorable DFS and OS.

28 May 2022 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Open access
DSDaniel Steiner
Daniel Steiner
CACihan Ay
Cihan Ay
Venous thromboembolism (VTE) is a common complication in cancer patients, which is associated with increased morbidity and mortality as well as high risk of VTE recurrence and bleeding. Furthermore, it impairs quality of life, interferes with anti-cancer treatment schedules, and increases costs. Therefore, identifying patients at high VTE risk and primary prevention are of clinical importance. In ambulatory patients, specific risk assessment models and clinical trials on primary thromboprophylaxis with low-molecular-weight heparins and direct oral factor Xa inhibitors are available. In hospitalized medical patients, there is lack of evidence. In surgical patients, no specific VTE risk assessment tools have been developed. However, extended thromboprophylaxis after major abdominal and pelvic cancer surgery is recommended because VTE risk persists beyond hospital discharge. In this review, we provide an overview on thromboprophylaxis strategies for patients with cancer in the ambulatory, hospitalized, and surgical setting. We also highlight recent advances and discuss evidence gaps.